FindTrial
Sign In

Can imeglimin be used in newly diagnosed type 2 diabetes patients with similar effect as metformin

To evaluate the effect of Imeglimin vs metformin on blood glucose and HbA1c in newly diagnosed type 2 diabetes mellitus patients - A randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/07/071491
Enrollment
60
Registered
2024-07-29
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Imeglimin group: Based upon inclusion and exclusion criteria, patient will be started on Tab.IMEGLIMIN 1000mg twice daily after food for 3 months Control Intervention1: Metformin group:

Sponsors

Department of general medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed type 2 diabetes patients 2. HbA1c less than 9% 3. eGFR more than 45

Exclusion criteria

Exclusion criteria: 1. Known type 2 diabetes patients on treatment 2. Known type 1 and type 3 diabetes 3. HbA1c more than 9% 4. Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
To measure the effect of imeglimin and metformin on blood sugars and HbA1c.Timepoint: Day 90 after starting the drug—

Secondary

MeasureTime frame
To compare the effect of imeglimin with metformin on blood sugar levels & HbA1cTimepoint: Day 90 after starting the drugs—

Countries

India

Contacts

Public ContactS N Meenakshi Sundari

SRM medical college hospital and research centre

meenakss1@srmist.edu.in94442449933

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026